top of page


grey wave2.png


Eveliqure is a clinical-stage biotechnology company that has developed a proprietary vaccine technology platform aiming at improving the quality of life for both the poor and the privileged by providing innovative medical solutions to fight diarrhoeal diseases.

ShigETEC, Eveliqure's vaccine candidate against Shigellae and enterotoxigenic E. coli, has successfully concluded its first Phase 1 clinical testing.

CALYXHA is a biotech start-up company developing novel small molecule anti-inflammatory drugs.

CALYXHA’s lead drug candidate targets multiple inflammatory diseases and is currently in preclinical development.

Algonist Biotechnologies is the first start-up biotech company spun out from CEBINA.

Algonist is developing novel drugs against chronic pain that have comparable efficacy to opioids but do not lead to addiction.

MAG – Molecular Architecture Group – takes a pragmatic and visionary approach to drug design. Leveraging chemistry, molecular-structural biology as well as computational technology, MAG-LAB aims to revolutionize the way molecular therapeutics are designed.

Get in touch

We're here to collaborate and innovate -

contact us to start the conversation

+43 (0)1 9092208

Internal innovative projects

The antihistamine azelastine as broad antiviral approach

As a short-term response to the COVID-19 pandemic, CEBINA, in collaboration with Professor Robert Konrat, a renowned structural biologist (Department of Structural and Computational Biology, University of Vienna, Austria) applied a novel computational approach to identify compounds to be repurposed as anti-COVID-19 drugs (Konrat at al, 2022). This approach led to the identification of azelastine, a generic anti-histamine medication available as nasal spray. CEBINA entered in partnership with URSAPHARM Arzneimittel GmbH to develop the azelastine nasal spray as anti-COVID-19 remedy. A Phase 2 proof-of-concept study performed in Europe confirmed the antiviral effect of the azelastine nasal spray in SARS-CoV-2 infected patients (Klussmann et al, 2023). CEBINA scientists proved a broad antiviral activity for azelastine, against influenza, RSV, and seasonal coronaviruses (Fischhuber et al, 2023). Several Phase 2 and 3 studies are ongoing.

bottom of page